100 related articles for article (PubMed ID: 3943093)
1. Levels of thymidylate synthetase during normal culture growth of L1210 cells.
Cadman E; Heimer R
Cancer Res; 1986 Mar; 46(3):1195-8. PubMed ID: 3943093
[TBL] [Abstract][Full Text] [Related]
2. Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil.
Washtien WL
Mol Pharmacol; 1984 Jan; 25(1):171-7. PubMed ID: 6708932
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthetase as target enzyme for the inhibitory activity of 5-substituted 2'-deoxyuridines on mouse leukemia L1210 cell growth.
De Clercq E; Balzarini J; Torrence PF; Mertes MP; Schmidt CL; Shugar D; Barr PJ; Jones AS; Verhelst G; Walker RT
Mol Pharmacol; 1981 Mar; 19(2):321-30. PubMed ID: 7231392
[No Abstract] [Full Text] [Related]
4. Paradoxical effect of cytosine arabinoside on mouse leukemia cell line L1210 cells.
Nakayama T; Sakamoto S; Sassa S; Suzuki S; Kudo H; Nagasawa H
Anticancer Res; 2005; 25(1A):157-60. PubMed ID: 15816533
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthetase and thymidine kinase activities and methotrexate cytotoxicity during growth of L1210 and Ehrlich ascites tumor.
Hullán L; Szikla K; Tusnády G; Holczinger L
Cancer Biochem Biophys; 1988 Nov; 10(2):131-9. PubMed ID: 3252959
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity of 5-fluoro-5'-O-nitro-2'-deoxyuridine, a new fluorinated pyrimidine derivative, in L1210 cultures.
Roberts D; Franklin P; Odom G; Peck C; Chwang TL
Mol Pharmacol; 1982 Nov; 22(3):760-5. PubMed ID: 6218391
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase.
Duch DS; Banks S; Dev IK; Dickerson SH; Ferone R; Heath LS; Humphreys J; Knick V; Pendergast W; Singer S
Cancer Res; 1993 Feb; 53(4):810-8. PubMed ID: 8428362
[TBL] [Abstract][Full Text] [Related]
8. Effects of new N-alkyl analogues of adriamycin on in vitro survival and cell cycle progression of L1210 cells.
Traganos F; Israel M; Silber R; Seshadri R; Kirschenbaum S; Potmesil M
Cancer Res; 1985 Dec; 45(12 Pt 1):6273-9. PubMed ID: 4063977
[TBL] [Abstract][Full Text] [Related]
9. Effects of aclacinomycin on cell survival and cell cycle progression of cultured mammalian cells.
Traganos F; Staiano-Coico L; Darzynkiewicz Z; Melamed MR
Cancer Res; 1981 Jul; 41(7):2728-37. PubMed ID: 6166368
[TBL] [Abstract][Full Text] [Related]
10. Autographa californica nucleopolyhedrovirus infection results in Sf9 cell cycle arrest at G2/M phase.
Braunagel SC; Parr R; Belyavskyi M; Summers MD
Virology; 1998 Apr; 244(1):195-211. PubMed ID: 9581791
[TBL] [Abstract][Full Text] [Related]
11. Changes in messenger RNA levels for the subunits of ribonucleotide reductase during the cell cycle of leukemia L1210 cells.
Thompson DP; Carter GL; Cory JG
Cancer Commun; 1989; 1(4):253-60. PubMed ID: 2700914
[TBL] [Abstract][Full Text] [Related]
12. Thymidylate synthetase levels as a factor in 5-fluorodeoxyuridine and methotrexate cytotoxicity in gastrointestinal tumor cells.
Washtien WL
Mol Pharmacol; 1982 May; 21(3):723-8. PubMed ID: 6213845
[TBL] [Abstract][Full Text] [Related]
13. Interaction of thymidylate synthetase and dihydrofolate reductase enzymes in vitro and in vivo.
Kawai M; Hillcoat BL
Cancer Res; 1974 Jul; 34(7):1619-26. PubMed ID: 4833915
[No Abstract] [Full Text] [Related]
14. Regulation of thymidylate synthetase in mouse leukemia cells (L1210).
Rode W; Scanlon KJ; Moroson BA; Bertino JR
J Biol Chem; 1980 Feb; 255(4):1305-11. PubMed ID: 6965493
[TBL] [Abstract][Full Text] [Related]
15. Thioguanine-induced S and G2 blocks and their significance to the mechanism of cytotoxicity.
Wotring LL; Roti Roti JL
Cancer Res; 1980 May; 40(5):1458-62. PubMed ID: 7370984
[TBL] [Abstract][Full Text] [Related]
16. [Studies on cell kinetics in leukemia using flow cytometry].
Yoshida K
Hokkaido Igaku Zasshi; 1982 Sep; 57(5):557-71. PubMed ID: 7152463
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle regulation of the G0/G1 transition in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines.
McGinn CJ; Pestalozzi BC; Drake JC; Glennon MC; Kunugi K; Otterson G; Allegra CJ; Johnston PG; Kinsella TJ
Cancer J; 2000; 6(4):234-42. PubMed ID: 11038143
[TBL] [Abstract][Full Text] [Related]
18. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
Gibbs DD; Theti DS; Wood N; Green M; Raynaud F; Valenti M; Forster MD; Mitchell F; Bavetsias V; Henderson E; Jackman AL
Cancer Res; 2005 Dec; 65(24):11721-8. PubMed ID: 16357184
[TBL] [Abstract][Full Text] [Related]
19. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
[TBL] [Abstract][Full Text] [Related]
20. Effects of the L isomer (+)-1,2-bis(3,5-dioxopiperazine-1-yl)propane on cell survival and cell cycle progression of cultured mammalian cells.
Traganos F; Darzynkiewicz Z; Melamed MR
Cancer Res; 1981 Nov; 41(11 Pt 1):4566-76. PubMed ID: 6171341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
